Last reviewed · How we verify
Cadonilimab (AK104)
Cadonilimab is a bispecific antibody that simultaneously blocks PD-L1 and TIM-3 pathways to enhance anti-tumor immune responses.
Cadonilimab is a bispecific antibody that simultaneously blocks PD-L1 and TIM-3 pathways to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Hepatocellular carcinoma, Other solid tumors (Phase 3 evaluation).
At a glance
| Generic name | Cadonilimab (AK104) |
|---|---|
| Also known as | Concurrent Chemoradiotherapy |
| Sponsor | Guangxi Medical University |
| Drug class | Bispecific monoclonal antibody; dual checkpoint inhibitor |
| Target | PD-L1 and TIM-3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By targeting both PD-L1 and TIM-3, cadonilimab overcomes dual immune checkpoint inhibition, allowing T cells to maintain activation and proliferation against cancer cells. This dual-checkpoint approach may provide superior efficacy compared to single-checkpoint inhibitors, particularly in tumors with high expression of both ligands.
Approved indications
- Non-small cell lung cancer
- Hepatocellular carcinoma
- Other solid tumors (Phase 3 evaluation)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Decreased appetite
- Elevated liver enzymes
Key clinical trials
- IC Plus Low-dose Radiation Plus Cadonilimab in LANPC (PHASE3)
- Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer (PHASE2)
- THIO and Cadonilimab in Resectable Hepatocellular Carcinoma (EARLY_PHASE1)
- Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer (PHASE3)
- Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix (PHASE2)
- Ligufalimab and Cadonilimab in Advanced Liver Cancers (PHASE2)
- A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence (PHASE2)
- A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cadonilimab (AK104) CI brief — competitive landscape report
- Cadonilimab (AK104) updates RSS · CI watch RSS
- Guangxi Medical University portfolio CI